FOR USE IN NERVE AGENT AND INSECTICIDE POISONING ONLY
CAUTION! PRIMARY PROTECTION AGAINST EXPOSURE TO CHEMICAL NERVE AGENTS AND INSECTICIDE POISONING IS THE WEARING OF PROTECTIVE GARMENTS INCLUDING MASKS DESIGNED SPECIFICALLY FOR THIS USE.
INDIVIDUALS SHOULD NOT RELY SOLELY UPON ANTIDOTES SUCH AS ATROPINE AND PRALIDOXIME TO PROVIDE COMPLETE PROTECTION FROM CHEMICAL NERVE AGENTS AND INSECTICIDE POISONING.
SEEK IMMEDIATE MEDICAL ATTENTION AFTER INJECTION WITH ATROPEN®.
A STERILE SOLUTION FOR INTRAMUSCULAR USE ONLY
Each prefilled auto-injector provides a dose of the antidote atropine in a self-contained unit, specially designed for self or caregiver administration. Four strengths of AtroPen® are available; they are AtroPen® 0.25 mg, AtroPen® 0.5 mg, AtroPen® 1 mg, and AtroPen® 2 mg.
The AtroPen® Auto-Injector is indicated for the treatment of poisoning by susceptible organophosphorous nerve agents having cholinesterase activity as well as organophosphorous or carbamate insecticides. The AtroPen ® Auto-Injector should be used by persons who have had adequate training in the recognition and treatment of nerve agent or insecticide intoxication. Pralidoxime chloride may serve as an important adjunct to atropine therapy.
The AtroPen ® is intended as an initial treatment of the muscarinic symptoms of insecticide or nerve agent poisonings (generally breathing difficulties due to increased secretions); definitive medical care should be sought immediately. The AtroPen® Auto-Injector should be administered as soon as symptoms of organophosphorous or carbamate poisoning appear (usually tearing, excessive oral secretions, wheezing, muscle fasciculations, etc.). In moderate to severe poisoning, the administration of more than one AtroPen® may be required until atropinization is achieved (flushing, mydriasis, tachycardia, dryness of the mouth and nose). (See DOSAGE AND ADMINISTRATION) In severe poisonings, it may also be desirable to concurrently administer an anticonvulsant if seizure is suspected in the unconscious individual since the classic tonic-clonic jerking may not be apparent due to the effects of the poison. In poisonings due to organophosphorous nerve agents and insecticides it may also be helpful to concurrently administer a cholinesterase reactivator such as pralidoxime chloride.
Published Studies Related to Atropen Auto-Injector (Atropine)
Atropine for the treatment of childhood myopia: changes after stopping atropine
0.01%, 0.1% and 0.5%. 
DESIGN: Prospective randomized double-masked clinical trial... CONCLUSION: There was a myopic rebound after atropine was stopped, and it was
Intrathecal atropine to prevent postoperative nausea and vomiting after Cesarean section: a randomized, controlled trial. [2011.08]
BACKGROUND: Postoperative nausea and vomiting (PONV) is a common adverse effect of intrathecal morphine, especially after Cesarean section. This randomized controlled trial investigated the effects of intrathecal administration of a small-dose of atropine on postoperative nausea and vomiting after Cesarean section... CONCLUSION: Intrathecal atropine had a significant antiemetic effect, making it a useful adjunct for intrathecal opioid-related PONV.
Comparative study between atropine and hyoscine-N-butylbromide for reversal of detomidine induced bradycardia in horses. [2011.05]
REASONS FOR PERFORMING STUDY: Bradycardia may be implicated as a cause of cardiovascular instability during anaesthesia. HYPOTHESIS: Hyoscine would induce positive chronotropism of shorter duration than atropine, without adversely impairing intestinal motility in detomidine sedated horses... CONCLUSION: Hyoscine is a shorter acting positive chronotropic agent than atropine, but does not potentiate the impairment in intestinal motility induced by detomidine. Because of severe hypertension, routine use of anticholinergics combined with detomidine is not recommended. POTENTIAL RELEVANCE: Hyoscine may represent an alternative to atropine for treating bradycardia. (c) 2010 EVJ Ltd.
Addition of atropine to submaximal exercise stress testing in patients evaluated for suspected ischaemia with SPECT imaging: a randomized, placebo-controlled trial. [2011.02]
PURPOSE: To evaluate the effects of the addition of atropine to exercise testing in patients who failed to achieve their target heart rate (HR) during stress myocardial perfusion imaging with single-photon emission computed tomography (SPECT)... CONCLUSION: The addition of atropine at the end of exercise testing is more effective than placebo in raising HR to adequate levels, without additional risks of complications. The use of atropine in patients who initially failed to achieve their maximal predicted HR is associated with a higher probability of achieving a diagnostic myocardial perfusion study.
Pharmacokinetic analysis of pralidoxime after its intramuscular injection alone or in combination with atropine-avizafone in healthy volunteers. [2010.12]
BACKGROUND AND PURPOSE: Treatment of organophosphate poisoning with pralidoxime needs to be improved. Here we have studied the pharmacokinetics of pralidoxime after its intramuscular injection alone or in combination with avizafone and atropine using an auto-injector device... CONCLUSIONS AND IMPLICATIONS: The two approaches, non-compartmental and compartmental, showed that the administration of avizafone and atropine with pralidoxime results in a faster absorption into the general circulation and higher maximal concentrations, compared with the administration of pralidoxime alone.
Clinical Trials Related to Atropen Auto-Injector (Atropine)
Trial Comparing Atropine to Atropine Plus a Plano Lens for the Sound Eye for Amblyopia in Children 3 to <7 Years Old [Active, not recruiting]
The purpose of the study is:
- To compare the effectiveness and safety of weekend atropine augmented with a plano lens
for the sound eye versus weekend atropine alone for moderate amblyopia (20/40 to 20/100)
in children 3 to less than 7 years old.
- To provide data on the response of severe amblyopia (20/125 to 20/400) to atropine
treatment with and without a plano lens.
Augmenting Atropine Treatment for Amblyopia in Children 3 to < 8 Years Old [Recruiting]
This study is designed to evaluate the effectiveness of adding a plano lens to weekend
atropine after visual acuity has stabilized with weekend atropine but amblyopia is still
present. Children ages 3 to <8 years with visual acuity of 20/50 to 20/400 in the amblyopic
eye will be enrolled in a run-in phase with weekend atropine until no improvement, followed
by randomization of eligible patients to weekend atropine treatment with a plano lens over
the sound eye versus without a plano lens over the sound eye. The primary objective is to
determine if adding a plano lens to weekend atropine will improve visual acuity in patients
with amblyopia still present after visual acuity has stabilized with initial treatment.
Trial Comparing Daily Atropine Versus Weekend Atropine [Completed]
The goals of this study are:
- To compare the visual acuity outcome in the amblyopic eye after 17 weeks of daily use of
atropine versus weekend-only use of atropine.
- To compare the proportion of patients achieving a complete treatment response (defined
as amblyopic eye acuity >20/25 or equal to that of the sound eye in the absence of a
reduction in the sound eye acuity from baseline) with daily atropine versus weekend-only
Adjunctive Atropine During Ketamine Sedation [Recruiting]
- Ketamine seems an obvious choice in the setting of an emergency department
- Ketamine leads to increased production of salivary and tracheal secretions
- Antisialagogues(atropine)therefore have been recommended as a routine adjunct
- We compare atropine with placebo as an adjunct to ketamine sedation in children
undergoing primary closure of lacerated wound
Effectiveness of Atropine and Glycopyrrolate to Reduce Hyper Salivation With Ketamine Sedation [Recruiting]
The purpose of this study is to determine if the antisialogogues (anti-salivary agents),
Atropine and Glycopyrrolate, are effective in reducing hypersalivation when sedating
patients with Ketamine for procedural sedation in the emergency department or abscess
clinic. The investigators will measure salivary flow rate by collecting oral secretions by
oral suctioning over a 30 minute time period starting with the administration of Ketamine.
The investigators hypothesize that patients who receive either atropine or glycopyrrolate
will have fewer oral secretions than patients who receive placebo.